teleo-codex/agents/vida/musings/research-2026-04-23.md

type	agent	date	status	research_question	belief_targeted
musing	vida	2026-04-23	active	Does the clinical/behavioral health determinants split still hold at the population level — and do modern pharmacological interventions like GLP-1s complicate or challenge the 80-90% non-clinical attribution?	Belief 2 (80-90% of health outcomes determined by non-clinical factors) — the foundational premise that's been running untested while Belief 1 has been disconfirmation-targeted for 5 consecutive sessions

Research Musing: 2026-04-23

Session Planning

Why this direction today: Sessions 22-25 have all targeted Belief 1 (compounding failure) for disconfirmation — and found only confirmation. This creates filter risk: I'm confident in Belief 1 partly because I keep testing it. But Belief 2 — that 80-90% of health outcomes are non-clinical — has been an untested premise for all of those sessions. It's the foundational claim underneath everything else.

Keystone belief (Belief 1) disconfirmation target: The structural form of the challenge: "What if GLP-1s are clinical interventions that achieve the outcomes behavioral interventions couldn't? If a pill can do what community, diet, exercise programs couldn't sustain, does clinical intervention re-emerge as primary driver?"

This would be important because:

• The McGinnis-Foege framework (1993) predates GLP-1s, CGMs, and AI-driven health coaching
• If pharmacological interventions can durably address metabolic dysfunction (obesity, T2DM, CV risk) at scale, the behavioral/clinical split may be more mutable than Belief 2 assumes
• GLP-1s are specifically interesting because they act on satiety neurocircuitry — they're addressing the BIOLOGICAL substrate of behavioral patterns, not just treating downstream disease

Disconfirmation target for Belief 2: A claim or data point that would genuinely threaten Belief 2:

"Modern pharmacological interventions (GLP-1s) demonstrate that biological dysregulation — not behavioral choice — is the primary driver of obesity outcomes, suggesting that clinical interventions may be more determinative than the McGinnis-Foege 40-50% behavioral attribution implies."

This wouldn't kill Belief 2 entirely (social determinants, stress, food environment, meaning structures still clearly matter), but would QUALIFY it significantly — the behavioral/biological interface is more clinically addressable than 1993 frameworks assumed.

Secondary direction: Provider consolidation The provider-consolidation-net-negative.md musing has been sitting as a CLAIM CANDIDATE for multiple sessions. Today is a good day to:

1. Search for recent evidence on hospital M&A + VBC transition dynamics
2. Possibly find disconfirmatory evidence (consolidation that enables VBC at scale)
3. Enrich the musing with 2025-2026 data

Tertiary: USPSTF GLP-1 gap Flag as active thread: the 2018 B recommendation on obesity predates GLP-1s and hasn't been updated. Searching for evidence of USPSTF process (petition, draft, timeline).

Disconfirmation Search Protocol

Actively looking for:

1. Studies showing that clinical interventions (not behavioral) are the dominant driver of mortality improvements in the last 20 years
2. Evidence that the "40-50% behavioral" attribution is methodologically contested
3. GLP-1 mechanism studies showing that obesity is primarily biological, not behavioral — challenging whether "behavioral change" was ever the right therapeutic target
4. International comparisons where high clinical spending correlates with good outcomes (challenging US-centric "spending doesn't work" narrative)
5. Evidence that provider consolidation enables VBC at scale (would challenge consolidation-net-negative musing)

Findings

Disconfirmation Attempt — Belief 2 (80-90% non-clinical factors): FAILED

Searched for: evidence that clinical interventions dominate health outcomes, or that GLP-1s as pharmacological agents challenge behavioral primacy.

What I found instead was mechanistic confirmation of Belief 2:

1. Science 2025 paper — hedonic eating and VTA dopamine: The most relevant disconfirmation candidate. GLP-1s work on VTA dopamine reward circuits — the biological substrate of "behavioral" overconsumption. This could suggest clinical intervention is more fundamental than behavioral intervention.

But the mechanism undermines the disconfirmation:

• The dopamine circuit ADAPTS during repeated semaglutide treatment — mice recover hedonic eating. The biology reasserts itself.
• This means GLP-1 requires continuous administration (confirming the Sessions 22-23 claims)
• The trigger remains environmental (engineered food continuously activating the reward circuit)
• Conclusion: behavioral factors dominate because they continuously activate the biological system. GLP-1 addresses the mechanism, not the trigger.

2. OECD Health at a Glance 2025 — the international comparison: The most powerful confirmation of Belief 2. The US data:

• US: $14,885/capita (2.5x OECD average $5,967)
• US: 17.2% GDP on health (vs. 9.3% OECD average)
• US: 78.4 years life expectancy — 4.3 years BELOW peer-country average
• US: BETTER than OECD on acute AMI (5.2% vs 6.5%) and stroke (4.5% vs 7.7%) 30-day mortality
• US: WORSE on preventable mortality (217 vs 145 per 100K — 50% worse)

The split is the evidence: excellent clinical performance (where clinical intervention is decisive) paired with catastrophic preventable mortality (where behavioral/environmental factors are decisive). Spending 2.5x OECD on clinical care achieves nothing on population health when behavioral/social determinants go unaddressed.

3. GLP-1 + Exercise (Frontiers 2025):

• GLP-1 > exercise for short-term weight loss
• Exercise > GLP-1 for lean mass preservation and long-term maintenance
• The combination is additive — neither replaces the other
• Critical mechanism: GLP-1 suppresses appetite → may reduce protein intake → muscle loss risk. Resistance training specifically mitigates this.
• Stopping GLP-1 without exercise infrastructure → weight regain

Behavioral factors (exercise, protein intake) remain necessary for optimal GLP-1 outcomes. The drug doesn't replace the behavior.

Verdict on Belief 2 disconfirmation: FAILED — but productively. The attempt revealed that GLP-1s validate Belief 2's core logic at the mechanistic level: "behavioral" patterns (overconsumption, addiction) are mediated through biological circuits (VTA dopamine), but the trigger remains behavioral/environmental (food engineering, food availability, social context). The most powerful pharmacological intervention for obesity still requires behavioral complement for sustained outcomes.

New framing generated: the behavioral/clinical dichotomy is false. Behavioral factors dominate because they continuously activate biological mechanisms. Clinical interventions (GLP-1) address the mechanism; behavioral/environmental interventions address the trigger. Both are necessary.

Provider Consolidation Thread: Confirmed and Qualified

GAO-25-107450 (September 2025):

• 47% of physicians consolidated with hospital systems in 2024 (up from <30% in 2012)
• Price effects: consistently increase after consolidation — not mixed
• Quality effects: same or lower — evidence is mixed but mostly null-to-negative

HCMR 2026 "Does Hospital Consolidation Promote Quality?":

• 37-year review: evidence is "decidedly mixed"
• Quality benefits buried in "black box of organizational changes" — conditional on what the consolidating entity does with increased scale and margin
• Price effects are the reliable signal; quality benefits are not

Qualification to provider-consolidation-net-negative musing: The thesis needs scope: "hospital consolidation reliably increases prices; quality effects are conditional on post-merger investment decisions." It's not simply net-negative — it's net-negative on average, with quality depending on internal investment decisions that are not structurally incentivized under current payment models.

VBC disconfirmation test: No evidence found that hospital-physician consolidation accelerates VBC transition at scale. The "ACOs and integrated delivery systems" carve-out in both reports is a different phenomenon — planned integration for VBC, not acquisition-driven consolidation.

WHO GLP-1 Guideline (December 2025):

First-ever global endorsement of GLP-1 for obesity. Conditional (not strong) recommendation — driven by cost, equity, and health system readiness concerns. Behavioral supplement recommendation carries only "low-certainty evidence." Important regulatory milestone: Essential Medicines List addition (September 2025 for T2DM, December 2025 conditional for obesity).

GLP-1 Addiction Applications:

33 clinical trials underway for substance use disorders. Same VTA dopamine mechanism as hedonic eating. AUD: RCT evidence showing reduced self-administration and craving. OUD: animal models only, human trials active (Harvard). Real-world analysis shows fewer ER visits/hospitalizations/deaths among people with SUD who take GLP-1s. This extends the "behavioral/biological interface" observation: addiction (like obesity) may be primarily a biological reward circuit condition, with GLP-1 as a common pharmacological mechanism.

ICER GLP-1 Payer Fiscal Analysis:

Blue Cross Blue Shield of Massachusetts: $300M+ GLP-1 cost in 2024 → $400M operating loss. Employer plans: >10x PMPM cost increase in 2023-2024. This is the payer-side mechanism for California's coverage elimination decision — not ideological, but financially existential for plan solvency.

---

Follow-up Directions

Active Threads (continue next session)

• Clinical AI deskilling/upskilling divergence file: All evidence compiled across Sessions 22-25 + today's context. The divergence should note the methodological asymmetry (upskilling evidence = "with AI present"; deskilling evidence = "post-removal RCT-quality"). Resolution criterion: a prospective study with post-AI training, no-AI assessment arm. This is overdue — highest priority for next session.
• Provider consolidation claim — ready for PR: Now have GAO-25-107450 + HCMR 2026 + existing musing. The qualified claim: "hospital consolidation reliably increases prices; quality effects are conditional on post-merger investment." Draft and open PR next session.
• GLP-1 SUD/addiction applications: 33 trials underway. This is 2-3 years from definitive clinical evidence. Monitor for trial results (especially AUD and OUD). The mechanistic story (shared VTA dopamine circuit) is strong enough to draft a claim now.
• OECD preventable mortality data: The US preventable mortality gap (217 vs 145/100K, 50% worse) is the strongest international evidence for Belief 2. This data point needs to be in the KB — either enriching existing SDOH claims or as a new international comparison claim.
• California Medi-Cal GLP-1 elimination cascades: Monitor whether NY, TX, FL face similar 2026-2027 budget pressures.

Dead Ends (don't re-run these)

• "GLP-1 durability beyond 3 years" — HealthVerity 2025 is the best available. No prospective studies exist yet (drug hasn't been out long enough).
• "BALANCE model as California fix" — voluntary, future-state, doesn't address state budget structure.
• "Evidence that behavioral programs reliably augment GLP-1 outcomes" — WHO found only low-certainty evidence; the exercise research shows resistance training specifically works, but generic behavioral programs don't have strong evidence of GLP-1 augmentation.
• "Hospital consolidation enables VBC at scale" — no evidence found in either GAO-25-107450 or HCMR 2026. The ACO/integration carve-out is different from acquisition-driven consolidation.
• "Clinical interventions dominate population health outcomes" — OECD data definitively shows clinical spending doesn't compensate for preventive/behavioral failures. This disconfirmation target is closed.

Branching Points (today's findings opened these)

• GLP-1 + addiction applications: Direction A (the VTA dopamine mechanism is strong enough to draft a claim about the shared biological basis of reward dysregulation conditions) vs. Direction B (wait for trial results — current evidence is RCT for AUD only, animal models for OUD). Pursue Direction A on mechanism; flag Direction B as monitoring thread.
• OECD preventable vs. treatable mortality split: The dual finding (US better on acute/treatable, worse on preventable) is extractable as either (a) evidence for Belief 2 or (b) a standalone claim about the US clinical excellence/preventive failure paradox. Both are worth drafting — the claim is more useful at the specific level.
• Behavioral/biological dichotomy reframe: Today's findings suggest a new framing worth developing: "behavioral factors dominate health outcomes because they continuously activate biological mechanisms — clinical interventions address the mechanism, behavioral/environmental interventions address the trigger." This is a theoretical contribution worth either a claim or a musing expansion.